Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 167.50 165.00 170.00 167.50 167.50 167.50 32,976 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 49.2 -56.5 -72.8 - 300

Amryt Pharma Share Discussion Threads

Showing 4576 to 4595 of 6675 messages
Chat Pages: Latest  195  194  193  192  191  190  189  188  187  186  185  184  Older
DateSubjectAuthorDiscuss
21/5/2019
14:03
Paps you are the most boring argumentative knowledgeless person I have ever witnessed. You are an unimportant stupid loser who deals in loose change and who thinks he is a trading guru. You are not you are a loser who is like a straw in the wind with shares. Good news and they are the best thing ever and bad news told you so. Please shut up forever you bore
positivitynicholas
21/5/2019
13:44
I had a peek at mdalos's last post to see what lies he was posting and LOL, LOL!!!! mdalos1 - 21 May 2019 - 13:13:39 - 4470 of 4472 Amryt Pharma - AMYT Flutterby... coincidentally and only today "I had 40k shares at the start of 2019 and sold all of them apart from a token 2k. Recently I started to buy back in and now have over 20k shares"... what a load of FLUTTER$h!te !!! BIGGEST LOSER GOING >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> LOL.LOL Here's what my Interactive Investor a/c says about my AMYT shareholding I have 21,961 AMYT shares at an average price of £0.1299. Book cost £2853.56. Value £2690.22. Total gain -£163.64. -5.72 If you look back through my posts since the start of the year, MADLOSS, you will see that I have documented all of my sales and buys in that period. UNLIKE YOU I DON'T DELETE ALL OF MY POSTS!!!!!!!!!!!!!!!!!!!!!!!! Get back in the sewer where you belong, MADLOSS. LOL.LOL.
papillon
21/5/2019
13:31
Here's the Novelion press release on the Amryt (AMYT) takeover of Novelion's wholly owned subsidiary, Aegerion. hTTps://ir.novelion.com/news-releases/news-release-details/novelion-therapeutics-announces-subsidiary-aegerion It gives the following enterprise value of US395m + US$146m to the enlarged company. How they arrive at that total figure of US$541m I have no idea: "The Recapitalization ascribes an enterprise value to Aegerion and Amryt of $395 million and $146 million, respectively, excluding cash and cash equivalents and subject to adjustment for accrued interest and certain payments that are due to the DOJ and the SEC. The key terms of the Recapitalization (the Restructuring Transactions), which are subject to Bankruptcy Court approval and other customary conditions, include the following:" The closing price of the Novelion share price (NVLN) last night was US$1.19 and the Mkt Cap was US$22.66m. I'll have a look later on to see how much debt Novelion/Aegerion has. I know it's a lot!!!!!! I don't believe Novelion is suspended following the announcement of the deal. It's looking like the deal wont be completed until the AP101 phase III trial result (Top Line Data) is known in H2 2019. Of course that doesn't mean that AMYT has to stay suspended until then. It's possible it will relist before then, but I'm only guessing..
papillon
21/5/2019
12:28
You are the mug selling them you muppet. You know absolutely nothing about investing
positivitynicholas
21/5/2019
12:02
The fact that institutions are ready to stump up cash at 27p shows they know value. Amryt managed to get this rto on the cheap b/c aegerion reputation has been trashed b/c of the lawsuit in my opinion. They are buying it via chapter 11...... which means getting it at a knock down price
digadee
21/5/2019
11:56
Hi greendragon. Good news. At the moment it all seems too good to be true. A possible placing price of 27.5p plus another possible 24p for AMYT shareholders if AP101 jumps all the hurdles currently in place!!!!!!!!!!!!!!!! I had 40k shares at the start of 2019 and sold all of them apart from a token 2k. Recently I started to buy back in and now have over 20k shares. Glad I started to buy back in, but disappointed I never kept all of my 40k. Still 20k+ is okay with me IF we see over 20 p on relisting and another 24p if AP101 proves a winner. If I can triple my money (at least) by 2020 then I'll be a happy bunny. PS I see that mdalos and purple have posted today. I have them on filter, but presume they have been negative with their comments. Couple of mugs!!
papillon
21/5/2019
11:42
Just saw the news guys, well done to all those who held tight. Well deserved uplift (hopefully) for holding throughout. It pretty much ticks all the boxes with funding, cost savings and not least the NASDAQ listing. All going well this is going to be a very different company by year's end! 👍
greendragon777
21/5/2019
11:26
You beat me to it, dim2602!!!!!!!!!!!!!!!! I was just about to post my comments when my phone rang so I was delayed. You rightly point out that success with AP101 could mean another 24p being paid to AMYT shareholders (in cash, or stock). BRING IT ON. BRING IT ON!!! "Contingent Value Rights ("CVRs") will be issued to Amryt stakeholders that could result in the payment of up to an additional $85m (settled in cash or stock) based on certain AP101 milestones being achieved"
papillon
21/5/2019
11:20
From today's RNS: "Pre-money implied transaction equity valuations: Amryt $120m and Aegerion $190.7m" "Pre-money implied transaction equity valuations: Amryt $120m and Aegerion $190.7m" "This equity raise will be placed at a 20% discount to the implied transaction equity value" Current Mkt Cap of AMYT is £34. Equivalent to US$43.2m. Where the AMYT valuation of US$120m comes from I have no idea!!!!!!!!!! That implies an share price of 34.375p!!!!!!!!!!!!!! If the placing price was to be determined by the implied value of AMYT ONLY that would give a placing price of 27.5p!!!!!!!!!!!!!!!!!!!!!!!! It sounds to good to be true, but I hope it is true!!!!!!!!!!!!!!!!!!!!! BRING IT ON!!!!!!!!!!
papillon
21/5/2019
11:04
"Transaction Highlights: -- Amryt has agreed to acquire Aegerion in an all-paper transaction -- The combined group had 2018 pro-forma combined revenues of $136.5m -- Pre-money implied transaction equity valuations: Amryt $120m and Aegerion $190.7m -- Contingent Value Rights ("CVRs") will be issued to Amryt stakeholders that could result in the payment of up to $85m (settled in cash or stock) based on certain AP101 milestones being achieved -- Amryt plans to raise $60m in equity concurrent with closing of the Transaction and certain Aegerion bondholders have agreed to backstop this equity raise -- This equity raise will be placed at a 20% discount to the implied transaction equity value " So the implied equity valuation of Amryt is $120m = £94m or 34p per share. New funds will be raised at a 20% discount to this, so 27.5p per share with up to another 24p if AP101 milestones are met. Assuming, the share price opens only at this discounted placing price, it will be a 120% gain from yesterdays close and that excludes the milestone payments.
dlm2602
21/5/2019
09:25
Yes, I agree, diamondstar.
papillon
21/5/2019
09:07
commiseration paps...I did try and say.....
purple11
21/5/2019
08:56
good to see you back on here diamondstar, the news today in my opinion is huge and i for one did not see it coming at all. Excellent work by the board to clinch this. Finally we will be listed on the nasdaq, better appreciation of the drug sector in the states. The company did well to keep this news quite. "Enlarged group to be re-admitted to AIM and Euronext Growth on closing with a planned dual-listing on NASDAQ"
digadee
21/5/2019
08:45
Paps - I think this is the reason for the spike in Amryt share price a few days ago, rather than a share tip.
diamondstar1
21/5/2019
08:40
Yes, I did suspect that Amryt was going to inlicense Myalepta for the EU market, but they have effectively killed 2 birds with one stone with the acquisition of Aegerion -they now have a presence in North America and can market episalvan (once approved) through these channels. Having the Myalepta global market is icing on the cake. I still have very high hopes for episalvan (AP101) in EB. I know that efficacy is modest i.e. about 10% improvement in primary endpoint. But this is acceptable, especially if you are the first to market. A stroke of Irish luck here - that Zorblisa failed in Ph 3. Look what happened to GSK’s SLE drug Benlysta (belimumab), which is a success with sales increasing year-on-year. Efficacy was modest, but GSK received FDA approval in 2011, as the first drug approved for SLE in over 50 years. So, all Amryt have to do is meet the primary endpoint for EASE Ph III. Amryt do not have to show fantastic efficacy, around 20-30%. The scenario would be different, if there were other drugs already approved for EB.
diamondstar1
21/5/2019
07:42
Good to see AMYT get up to £85m upside on AP101 (given current market cap is £26m)
waterloo01
21/5/2019
07:33
Wow! Am pretty sure someone here made the connection with Myalepta, was it Diamondstar? Well called whoever it was.
bermudashorts
21/5/2019
07:17
Need to absorb. Shares suspended so time to consider but looks like a transformative move
waterloo01
21/5/2019
07:09
Didn’t see that coming!
bazworth
15/5/2019
15:24
see how TRP and i3E get along once drilling starts in a couple of months....theyre big winners pappy...tuck a few away...you could get yourself a new lawnmower for the yard when they come in.gl p.s I knew you couldn't resist a little peek at my posts...
purple11
Chat Pages: Latest  195  194  193  192  191  190  189  188  187  186  185  184  Older
ADVFN Advertorial
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210620 17:13:45